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Summary
 
T cell tolerance to parenchymal self-antigens is thought to be induced by encounter of the T
cell with its cognate peptide–major histocompatibility complex (MHC) ligand expressed on the
parenchymal cell, which lacks appropriate costimulatory function. We have used a model sys-
tem in which naive T cell receptor (TCR) transgenic hemagglutinin (HA)-specific CD4
 
1
 
 T
cells are adoptively transferred into mice expressing HA as a self-antigen on parenchymal cells.
After transfer, HA-specific T cells develop a phenotype indicative of TCR engagement and are
rendered functionally tolerant. However, T cell tolerance is not induced by peptide–MHC
complexes expressed on parenchymal cells. Rather, tolerance induction requires that HA is
presented by bone marrow (BM)–derived cells. These results indicate that tolerance induction
to parenchymal self-antigens requires transfer to a BM-derived antigen-presenting cell that pre-
sents it to T cells in a tolerogenic fashion.
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T
 
he immune system has the ability to recognize and
neutralize pathogens. However, it must remain toler-
ant of self-antigens so as not to destroy what it has evolved
to protect. In the case of T lymphocytes, the majority of
cells with specificities for self-antigens are eliminated dur-
ing development in the thymus (1, 2). T cells whose TCRs
recognize self determinants not presented in the thymus
will mature and migrate to the peripheral lymphoid organs.
Therefore, additional mechanisms of peripheral tolerance
are needed to prevent the development of autoimmunity (3).
There appear to be several potential mechanisms for pe-
ripheral T cell tolerance. In the simplest case, naive T cells
ignore parenchymal tissues expressing their cognate antigen
(4, 5). The lack of expression of T cell costimulatory
ligands such as B7 on the antigen-expressing parenchyma
may play a role in preventing these T cells from becoming
activated (6, 7). The most profound form of tolerance is
physical deletion of potentially autoreactive T cells (8–10),
a process that may proceed via an initial activation phase
before ultimate elimination (11–13). T cell inhibition by
expression of Fas ligand by cells in certain organs such as
the eye (14) and testis (15), as well as downregulation of the
TCR (16) or coreceptor molecules (i.e., CD8) (17), repre-
sent additional mechanisms for self-tolerance generation
observed in certain model systems.
Another form of peripheral tolerance that is commonly
observed is the induction of anergy (18). Anergic T cells
are neither deleted nor altered with regard to expression of
their TCR and coreceptor molecules, but are refractory to
antigenic stimuli that would activate naive T cells (19–21).
The two-signal model predicts that a T cell will become
activated when its TCR recognizes the cognate MHC–
peptide ligand on the surface of a professional (i.e., bone
marrow [BM]
 
1
 
–derived) APC that also expresses a second
costimulatory signal, whereas TCR engagement in the ab-
sence of costimulation results in anergy (22). Consistent
with this model is the observation that transgenic expres-
sion of an allo-class II MHC molecule on pancreatic islet 
 
b
 
cells, which do not express costimulatory activity, induces
anergy in the cognate CD4
 
1
 
 T cell population (20),
whereas coexpression of B7 together with allo-class II
MHC on 
 
b
 
 cells diminishes their capacity for tolerance in-
duction (23). The more recent observation that anergy
induction by injection of soluble antigen can be blocked in
vivo by preventing B7–CTLA4 interaction (24) suggests
 
1
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that counterregulatory pathways also influence the ultimate
outcome of TCR engagement.
In contrast to parenchymal cells, antigen presentation by
BM-derived cells is generally considered to be stimulatory
rather than tolerogenic. Nonetheless, antigen presentation
by some subsets of BM-derived cells, such as B cells, have
been shown to induce tolerance in vivo (25, 26). There-
fore, it is possible that tolerance induction to peripheral
self-antigens could involve transfer to a subset of BM-
derived APCs specialized to present them to T cells in a
tolerogenic fashion. To distinguish whether tolerance in-
duction to parenchymal self-antigens involves direct pre-
sentation versus transfer to a tolerizing BM-derived APC,
we have developed a model in which naive TCR trans-
genic CD4 cells specific for the hemagglutinin (HA) anti-
gen are rendered anergic after adoptive transfer into mice
expressing HA as a parenchymal self-antigen. Analysis of
tolerance induction in parent 
 
®
 
 
 
F
 
1
 
 chimeras demonstrates
the absolute requirement of transfer to and presentation by
BM-derived APCs in tolerance induction.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
The 7.1 kb C3(1) genomic
clone (27) was provided by Elizabeth Wilson (University of
North Carolina, Chapel Hill, NC). The initiation codon (ATG)
located in the first exon at 
 
1
 
55 bp as well as a potential cryptic
initiation codon (ATG) at 
 
1
 
104 bp were altered to ATT and TTG,
respectively, by subcloning the 5
 
9
 
 4.4-kb HindIII–PstI fragment
into the pALTER-1 plasmid (Altered Sites In Vitro Mutagenesis
System; Promega, Madison, WI) and following the manufac-
turer’s protocol for site-directed mutagenesis using the mutagenic
oligonucleotide 5
 
9
 
-CAA CAT TAA GCT GGT GTT TCT
ATT CTT GTT GGT CAC CAT CCC CAT TTG CTG CTT
TGC CAG. After DNA sequencing was performed to confirm
the correct alterations, the HindIII–PstI fragment was ligated into
the pGem4 vector (Promega). The 1.7-kb HA gene coding se-
quence derived from the influenza virus A/PR/8/34 (Mount Si-
nai strain) (28) was ligated downstream of the C3(1) promoter as
a SalI–BamHI fragment. The 2.4 kb 3
 
9
 
 fragment of C3(1) was
PCR amplified with Pfu polymerase (Stratagene, La Jolla, CA)
using the primers 5
 
9
 
-GGT TCT GGA TCC AGT ATT CTA
and 5
 
9
 
-CGT AGA TGA TCA GTG GGT GTG GG to add
BamHI (5
 
9
 
) and BclI (3
 
9
 
) restriction sites, respectively, and then
ligated into the BamHI site downstream of the HA gene.
The C3-HA expression cassette was isolated by digesting with
HindIII and KpnI followed by gel purification using Elutip DNA
purification columns (Schliecher & Schuell, Inc., Keene, NH)
before microinjection into fertilized B10.D2 embryos (performed
at the University of Michigan Biomedical Research Core Facili-
ties, Ann Arbor, MI). Transgenic progeny were identified by
PCR analysis of DNA extracted from tail biopsies using the prim-
ers 5
 
9
 
-GTG TTC TTT GGC TCT TCT TCG and 5
 
9
 
-GCA
GAG AAA TCT GAT CAT AAC. Southern blot analysis indi-
cated that the C3-HA transgenic founder line No. 142 contained
approximately three intact copies of the transgene (data not
shown).
The TCR transgenic mouse line 6.5 (reference 29; provided
by Harald von Boehmer, Institut Necker, Paris, France) that
expresses a TCR recognizing an I-E
 
d
 
 restricted HA epitope
(
 
110
 
SFERFEIFPKE
 
120
 
) was backcrossed 8 generations onto the
 
B10.D2 genetic background. Transgenic progeny were typed ei-
ther by flow cytometry using the 6.5 mAb (see below) or by
PCR analysis using the primers 5
 
9
 
-AGT CGT GCC CTG GTC
CG and 5
 
9
 
-GCT GCA GTC ACC CAA AGC.
 
Reverse Transcriptase PCR Analysis of Tissue Expression of Trans-
gene.
 
Tissues were homogenized in Trizol buffer (GIBCO
BRL, Gaithersberg, MD) and RNA purified as recommended by
the manufacturer. 1 
 
m
 
g of DNAsed RNA was reverse transcribed
by standard methods and PCR amplified for 50 cycles using
primers to the ubiquitously expressed 
 
b
 
-2–microglobulin (
 
b
 
2M)
gene, 5
 
9
 
-GAT GCT GAT CAC ATG TCT CG and 5
 
9
 
-CAA
ATT CAA GTA TAC TCA CGC, as well as the C3-HA trans-
gene transcript, 5
 
9
 
-CAT TTG CTG CTT TGC CAG TG and
5
 
9
 
-GGT TTC CCA AGA GCC ATC. Both primer sets spanned
introns so that the resulting PCR products of 280 (
 
b
 
2M) and 310 bp
(C3-HA) could only be amplified from cDNA and not from con-
taminating genomic DNA. PCR reactions were electrophoresed
on 4% polyacrylamide gels and stained with ethidium bromide.
 
Flow Cytometry.
 
10
 
6
 
 cells were preincubated with the Fc-
 
g
 
receptor blocking antibody 2.4G2 (HB-197; American Type
Culture Collection, Rockville, MD). mAbs used for staining were:
biotinylated anti-clonotypic TCR (6.5, provided by H. von Boeh-
mer); avidin-PE; and FITC-conjugated anti-CD4 (CT-CD4;
Caltag, Burlingame, CA). Cy-chrome–conjugated anti-CD4
(RM4-5), FITC-conjugated anti-CD44 (IM7), and FITC-conju-
gated anti-CD45RB (16A) were purchased from PharMingen
(San Diego, CA). 100,000 lymphocyte-gated events were col-
lected for double staining, and 200,000 CD4
 
1
 
 gated events were
collected for triple staining on a FACScan
 
Ò
 
 (Becton Dickinson,
San Jose, CA).
 
Adoptive Transfer.
 
Pooled axillary, inguinal, cervical, and mes-
enteric LNs from the 6.5 transgenic mice were dissociated in
RPMI media (GIBCO BRL), passed over nylon mesh, and
washed in RPMI. After FACS
 
Ò
 
 staining to determine the propor-
tion of clonotypic CD4 cells, cell preparations containing 2.5 
 
3
 
10
 
6
 
 clonotypic cells were injected intraperitoneally in 0.5 ml sterile
HANKS buffer (GIBCO BRL) into unirradiated male recipients.
T cell transfers using intraperitoneal versus intravenous delivery
yielded equivalent results (data not shown). For control transfers,
pooled LN cells from nontransgenic (NT) mice were injected
into recipients with the total number of transferred cells equaling
that given to mice receiving 6.5 clonotypic T cells. At the indi-
cated time points after transfer, pooled LN and spleen were ex-
tracted from the recipients and dissociated in CTL media (RPMI
with 10% FBS [HyClone, Logan, UT], 0.1 mM 2-ME, 2 mM
 
l
 
-glutamine,1 mM sodium pyruvate, and 1
 
3
 
 nonessential amino
acids and penicillin/streptomycin solutions (Sigma Chemical Co.,
St. Louis, MO)) for further analysis. Time course studies indi-
cated that the responses of the clonotypic CD4 cells after transfer
into the respective recipients were manifested by 9 d and persisted
through 21 d after transfer (data not shown). Although data pre-
sented is exclusively from LN, T cells recovered from either the
LN or spleen of the same recipient always exhibited a similar phe-
notype (data not shown). For transfers into parent 
 
®
 
 
 
F
 
1
 
 chimeras,
the 6.5 mice were made H-2
 
bxd
 
 by mating with NT C57BL/6
mice. Before adoptive transfer, LN T cells from 6.5 bxd progeny
were depleted of endogenous class II–expressing cells using
streptavidin-conjugated dynabeads (DYNAL, Lake Success, NY)
and the biotinylated anti-I-E
 
d
 
 mAb 14.4.4s as per the manufac-
turer’s instructions.
 
Proliferation and IL-2 Assays.
 
1.5 
 
3 
 
10
 
5
 
 LN cells or spleno-
cytes extracted from transfer recipients were incubated in round-
bottomed 96-well tissue culture plates with the indicated concen- 
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tration of synthetic HA peptide. In parent 
 
®
 
 
 
F
 
1
 
 chimera experi-
ments, 5 
 
3 
 
10
 
4
 
 cells prepared from the transfer recipients were
mixed with
 
 
 
10
 
5
 
 splenocytes from an unmanipulated NT mouse
(F
 
1
 
, bxd) and HA peptide. For proliferation assays, 72-h cultures
were pulsed with 1 
 
m
 
Ci [
 
3
 
H]thymidine and incubated an addi-
tional 24 h before harvest and determination of the amount of in-
corporated radioactive counts. LN and spleen APCs extracted
from C3-HA mice did not express endogenous HA peptide on
their surface in sufficient quantities to either stimulate or suppress
the response of naive clonotypic cells in this assay (data not
shown). To measure IL-2 levels, media was removed from 72-h
cultures and analyzed using a murine IL-2 ELISA kit (Endogen,
Woburn, MA) as per the manufacturer’s instructions. Individual
data points in both proliferation and IL-2 assays represent the av-
erage of triplicate wells.
 
Generation of BM Chimeras.
 
2-mo-old mice were treated
with 1,000 rads of ionizing radiation and then given 4 
 
3 
 
10
 
6
 
 BM
cells depleted of T cells using complement and the mAbs J1j
(anti-Thy1), C3PO (anti-CD2), RL172 (anti-CD4), and 3.155
(anti-CD8). Animals were given a 2–3-mo recovery period be-
fore performance of T cell transfer experiments. For parent 
 
®
 
 
 
F
 
1
 
chimeras, H-2
 
bxd
 
 BM recipients (generated by mating C3-HA
transgenic and NT mice [on a B10.D2 background, H-2
 
d
 
] with
C57BL/6 mice [H-2
 
b
 
]) received BM grafts from NT B10.D2 or
C57BL/6 mice. After reconstitution, blood samples were stained
with the mAbs 14.4.4s (anti-I-E
 
d
 
) and Y-3P (anti-I-A
 
b
 
) to con-
firm the BM haplotypes before initiation of T cell transfer experi-
ments.
 
Results
 
Generation of C3-HA Transgenic Mice.
 
The rat C3(1)
gene encodes a polypeptide that comprises one of the three
subunits of the oligomeric prostatic steroid-binding pro-
tein, which is the predominant protein present in rat pros-
tatic fluid (30). A large genomic fragment containing the
three coding exons, two introns and several kb of both 5
 
9
 
and 3
 
9
 
 flanking sequences was previously shown in trans-
genic mice to direct the expression of C3(1) mRNA in
several organs. In addition to male reproductive organs
such as the prostate and testes, the C3(1) transgene was also
expressed in nonreproductive tissues such as the heart, sali-
vary gland, skeletal muscle, and lung (31). A 7.1-kb C3(1)
genomic fragment (27) was modified by ligating the coding
sequence for the influenza HA gene (PR8 Mount Sinai
strain) into the C3(1) second exon. The C3(1) initiation
codon, located within the first exon, was altered by site-
directed mutagenesis so that translation of the chimeric
transgene mRNA would begin and terminate within the
HA coding sequence (Fig. 1). The C3-HA expression cas-
sette was microinjected into fertilized B10.D2 embryos. A
transgene line No. 142 was characterized that contained
approximately three intact copies of the transgene (data not
shown).
Using reverse transcriptase (RT)-PCR analysis, HA
transcript–derived PCR products were consistently gener-
ated from RNA prepared from several peripheral organs
including male sex accessory tissues such as the prostate,
testis, vas deferens, and seminal vesicles, as well as a number
of nonreproductive organs including the salivary gland,
kidney, heart, and lung. HA expression was detected in-
consistently in other tissues such as the thymus, BM, and
Figure 1. C3-HA transgene expression vector. The C3-HA transgene
expression cassette consists of a 7.1-kb C3(1) HindIII–KpnI genomic
fragment in which the 1.7-kb HA cDNA has been ligated into the second
exon of C3(1). The natural initiation codon within the first exon of C3(1)
was altered (*) so that translation would initiate and terminate within the
HA cDNA sequence.
 
Table 1.
 
RT-PCR Analysis of Transgene mRNA Distribution
 
Organ HA mRNA expression
Male reproductive
Ventral prostate
 
1
 
*
 
Dorsal lateral prostate
 
1
 
Seminal vesicles
 
1
 
Testis
 
1
 
Vas deferens
 
1
 
Bulbourethral gland
 
1
 
Penis
 
1
 
Epididymis
 
1
 
/
 
2
 
‡
 
Coagulating gland
 
2
 
§
 
Lymphoid tissues
Bone marrow
 
1
 
/
 
2
 
Thymus
 
1
 
/
 
2
 
Lymph node
 
1
 
/
 
2
 
Spleen
 
2
 
Others
Lung
 
1
 
Heart 1
Salivary gland 1
Kidney 1
Skeletal muscle 1
Intestine 1/2
Bladder 2
Liver 2
Pancreas 2
Brain 2
RNA was prepared from the indicated organs of C3-HA (line No. 142)
transgenic mice and subjected to RT-PCR analysis.
*1, tissues displayed reproducibly strong HA-specific cDNA derived
PCR products.
‡1/2, tissues displayed weak or inconsistent PCR products, suggestive
of low HA mRNA levels that were near the threshold detection level
of the assay.
§2, tissues did not show any evidence of HA mRNA expression.1558 CD41 T Cell Tolerance
LNs, suggesting that HA mRNA expression levels were
near the threshold detection limit for the RT-PCR assay
(Table 1). Anti-HA antibody staining of RT-PCR–posi-
tive tissues did not reveal any signal above background
(data not shown), suggesting that HA expression in the No.
142 line was relatively low.
Naive HA-specific CD41 T Cells Become Tolerant when
Transferred into HA-expressing Transgenic Mice. To study
how HA-specific CD41 T cells respond when they en-
counter HA antigen expressed in the C3-HA transgenic
mice, naive clonotypic cells from 6.5 TCR transgenic mice
(expressing a TCR specific for an I-Ed–restricted HA
epitope) were adoptively transferred into unirradiated C3-
HA and NT animals. 9 d after transfer into NT animals, the
clonotypic CD4 cells were retrieved from pooled LN and
their frequency was determined by FACSÒ (Fig. 2 A). In a
representative NT transfer recipient, the clonotypic cells
(which stain positively for both CD4 and the 6.5 TCR)
comprised 0.24% of the total lymphocytes. The clonotypic
CD4 cells were also present in a C3-HA recipient in ap-
proximately the same proportion (0.21%). The background
staining, determined by analyzing control NT and C3-HA
mice that had received T cell preparations from NT mice,
was 0.04 and 0.02%, respectively. Comparing the average
proportion of clonotypic T cells present in the two groups
of recipients, there might have been slightly fewer clono-
typic cells in the C3-HA mice (Fig. 2 B). Although the
double staining did not reveal a significant difference be-
tween the number of clonotypic T cells that were present
in the NT and those present in C3-HA recipients, triple
staining using the cell surface markers CD44 and CD45RB
suggested that the HA-specific CD4 cells had in fact en-
countered and responded to their cognate antigen after
transfer into the C3-HA recipients (Fig. 2 C). Clonotypic
T cells transferred into NT recipients exhibited CD44 and
CD45RB expression profiles which were similar to those
observed on gated non-clonotypic CD4 cells from the
same animals, suggesting that these clonotypic cells re-
mained in a naive state. In contrast, the clonotypic T cells
retrieved from the C3-HA recipients had upregulated
CD44 expression and downregulated CD45RB expression
relative to the nonclonotypic CD4 cells, a phenotype con-
sistent with antigen recognition. The average mean fluores-
cence values for each marker on the clonotypic cells were
altered approximately twofold in the C3-HA recipients
(data not shown). That the clonotypic, but not the nonclo-
notypic, T cells in the C3-HA and NT transfer recipients
exhibited different expression profiles for CD44 and
CD45RB consistent with the presence or absence of HA,
respectively, provides confirmatory evidence that the cell
population in the upper right quadrant of the FACSÒ plots
(Fig. 2 A) are in fact clonotypic CD4 cells.
Functionally, the HA-specific CD4 cells retrieved from
the C3-HA recipients were refractory to antigenic stimula-
tion by their cognate peptide epitope. In comparison to
clonotypic cells retrieved from NT recipients, they were
impaired in their abilities to proliferate (Fig. 3 A) and se-
crete IL-2 (Fig. 3 B) when cultured with APCs pulsed with
HA peptide. IL-2 secretion by clonotypic CD4 cells re-
trieved from C3-HA recipients was consistently greater
than sevenfold lower than cells retrieved from NT recipi-
ents even at shorter (48-h) in vitro culture times (data not
shown). These clonotypic T cells did not appear to have
acquired suppressor activity or to mediate cytolytic destruc-
Figure 2. FACSÒ analysis of clonotypic HA-specific CD4 cells after adoptive transfer into C3-HA transgenic mice. HA-specific CD4 cells were re-
trieved from the LN of C3-HA and NT recipients 9 d after transfer of 2.5 3 106 clonotypic cells. Two-color staining from representative transfer recipi-
ents (A) was performed using FITC-labeled anti-CD4 and biotinylated 6.5 followed by PE-labeled streptavidin. Clonotypic cells (upper right quadrant)
stain positively for both CD4 and 6.5 surface markers. As controls, LN preparation taken from NT and C3-HA recipients of NT T cells were also stained.
The relative percentage of cells in each quadrant is shown in the upper right corner of each plot with the percentage of cells in the upper right quadrant
in larger print. Bar graph showing the average frequency of clonotypic CD4 cells in the different transfer recipient groups (mean 6 SEM, n 5 4) (B)
Three color staining was performed using cy-chrome–labeled anti-CD4, FITC-labeled CD44 or CD45RB, and biotinylated 6.5 followed by PE-labeled
streptavidin. (C) Histogram plots of representative clonotypic transfer recipients for CD44 and CD45RB expression on gated clonotypic (C) and nonclo-
notypic (NC) CD4 cells.1559 Adler et al.
tion of APCs presenting HA peptide in culture, since clo-
notypic cells retrieved from NT recipients proliferated
equivalently when mixed with either the clonotypic T cells
retrieved from C3-HA recipients or control cell prepara-
tions (Fig. 4). Furthermore, HA-expressing organs did not
exhibit any gross or histological evidence of autoimmunity
after transfer of clonotypic T cells (data not shown). Taken
together, these results indicate that the HA-specific CD4 cells
had been rendered tolerant upon transfer into HA-express-
ing transgenic mice.
HA Expression on BM-derived Cells Is Not Required for Tol-
erance Induction. RT-PCR analysis (Table 1) indicated
that HA mRNA was being expressed in several peripheral
tissues and perhaps in the BM as well. To ascertain whether
T cells were being tolerized as a result of HA expression
by BM-derived cells, parenchymal cells, or both, a set of
BM chimeras were generated in which BM from NT ani-
mals was used to reconstitute lethally irradiated C3-HA
transgenic animals (NT ® C3-HA), and conversely C3-
HA BM was used to reconstitute irradiated NT mice (C3-
HA ® NT). As positive and negative controls for tolerance
induction, C3-HA BM–reconstituted C3-HA recipients
(C3-HA  ®  C3-HA) and NT BM–reconstituted NT recip-
ients (NT ® NT) were also analyzed. HA-specific 6.5 clo-
notypic T cells retrieved from the C3-HA ® NT chimeric
transfer recipients did in fact exhibit an impaired prolifera-
tive response to HA peptide (Fig. 5). This tolerization
might have resulted from low levels of HA expression in
the BM, although we cannot rule out the possibility that
contaminating APCs in the BM preparation that had ac-
quired HA antigen from the periphery of the donor were
mediating this effect. Nonetheless, tolerance induction in
the NT ® C3-HA chimeras was also apparent, indicating
that HA need not be expressed in BM-derived cells for tol-
erance induction to take place.
Tolerance Induction Is Exclusively Mediated by an Antigen
Transfer Pathway Involving BM-derived APCs. Because tol-
erance induction did not appear to require that HA be ex-
pressed in BM-derived cells, either the HA expressing pa-
renchymal cells were able to directly induce tolerance, or
Figure 3. Clonotypic CD4
cells exhibit impaired response to
antigenic stimulation after adop-
tive transfer into C3-HA trans-
genic recipients. (A) In vitro
proliferative response of clono-
typic cells, retrieved 9 d after
transfer, to peptide stimulation.
LN cells prepared from NT
(closed circles; n 5 3), C3-HA
transgenic (open circles; n 5 3),
and control (closed squares; n 5 1)
recipients were cultured with the
indicated concentration of syn-
thetic HA peptide. (B) T cell
proliferation was measured by
[3H]thymidine incorporation,
and data were expressed as the
total number of incorporated ra-
dioactive counts (cpm, mean 6
SEM). IL-2 secretion by clono-
typic cells stimulated in vitro.
Media were collected from 72-h
cultures with (hatched bars) and
without (solid bars) 100 mg/ml
HA peptide and tested by
ELISA. Data is expressed as pg/
ml IL-2 (mean 6 SEM, n 5 3).
Figure 4. Tolerized clonotypic T cells do not inhibit the proliferative
response of naive clonotypic T cells in vitro. Equal parts of the indicated
LN preparations taken from day 9 transfer recipients were combined; tol-
erized T cells with control cells (C3-HA 1 C), naive T cells with control
cells (NT 1 C), and naive with tolerized T cells (NT 1 C3-HA). 1.5 3
105 total cells were cultured in vitro with (hatched bars) or without (solid
bars) 100 mg/ml HA peptide and proliferation was determined by
[3H]thymidine incorporation (cpm, mean 6 SEM, n 5 3).1560 CD41 T Cell Tolerance
the acquired BM-derived APCs shed antigen and presented
the I-Ed–restricted HA epitope in a tolerogenic manner.
To distinguish between these possibilities, parent ® F1 chi-
meras were generated in which the parenchymal cells ex-
pressing HA expressed the appropriate MHC haplotype for
HA epitope presentation (H-2d), whereas the BM ex-
pressed either the restricting (H-2d) or a nonrestricting (H-
2b) MHC haplotype for the transgenic TCR. C3-HA
transgenic mice (F1, bxd) were reconstituted with either
NT H-2d BM (H-2d ® H-2bxd/HA) or NT H-2b BM (H-
2b ® H-2bxd/HA). Clonotypic CD4 cells prepared from
H-2bxd F 1 6.5 transgenic mice were depleted of endoge-
nous APCs before adoptive transfer.
As expected, in two independent experiments, clono-
typic cells transferred into H-2d ® H-2bxd/HA chimeras
exhibited impaired proliferative responses to HA peptide in
vitro relative to NT chimeric controls. In contrast, clono-
typic cells retrieved from H-2b ® H-2bxd/HA chimeras
were not tolerized, proliferating as vigorously as did the
NT control chimeras (Fig. 6 A). As an increase in expres-
sion of CD44 on the surface of clonotypic T cells correlates
with antigen recognition and the induction of tolerance
(see Fig. 2), the clonotypic CD4 cells from experiment 1
were analyzed by FACSÒ to quantitate both their frequen-
cies as well as their level of surface CD44 expression. Al-
though similar numbers of clonotypic T cells were mea-
sured in each group (Fig. 6 B), only clonotypic cells in the
positive control group (H-2d ® H-2bxd/HA) exhibited in-
creased CD44 expression levels relative to the nonclono-
typic CD4 cells (Fig. 6). The finding that the clonotypic
CD4 cells retrieved from the H-2b ® H-2b3d/HA experi-
mental group expressed low levels of CD44 indicated that
they had not come into contact with the cognate I-Ed-HA
peptide complex in vivo. Taken together, these results are
inconsistent with a mechanism by which T cells are directly
tolerized by HA-expressing parenchyma. Furthermore, the
data also argues against the presence of radio-resistant host
APCs (H-2bxd) that were capable of inducing tolerance.
That tolerance induction required BM-derived APCs to
express the restricting MHC haplotype clearly indicates
that tolerance was induced by APCs that had acquired HA
by means of an antigen transfer pathway.
Discussion
Several previous studies have described in vivo model
systems to study peripheral T cell tolerance. Although
some systems have examined heterogenous T cell popula-
tions, analysis at the level of a single T cell specificity has
been achieved by breeding double transgenic mice that ex-
press both a model antigen in the periphery and the cog-
nate TCR on a large fraction of their mature T cells (32).
The limitation of this approach is that T cells might not be-
have normally when the T cell repertoire is so heavily
dominated by the clonotypic specificity. This problem can
be circumvented by adoptively transferring a relatively
small number of clonotypic T cells, derived from TCR
transgenic mice, into mice with a normal T cell repertoire
(33). In this study we have used such an adoptive transfer
system to study peripheral tolerance mechanisms for a clo-
notypic CD41 T cell population to a peripherally expressed
self-antigen.
Naive HA-specific CD4 cells adoptively transferred into
transgenic mice that express HA in several tissues become
functionally tolerized as evidenced by their inability to pro-
liferate and secrete IL-2 when reextracted and cultured
with peptide-pulsed APCs. Although we cannot rule out
the possibility that a portion of these tolerized T cells were
deleted or had downregulated expression of their CD4 or
clonotypic TCR molecules, our data do indicate that a sig-
nificant number of these T cells persist that express normal
levels of CD4 and TCR but are refractory to subsequent
antigenic stimulation in vitro. These results are compatible
with anergy as the form of tolerance that is induced in this
system. Given that some of the transgenic T cells probably
express both endogenous and transgenic TCRs, the ob-
served nonresponsiveness could still reflect deletion of
transgenic cells bearing single transgenic TCRs, leaving
CD441 T cells bearing two TCRs. However, Figs. 2 and 6
demonstrate that the proportion of clonotype-positive cells
expressing CD44 goes from z5% in control animals to
.60% in the HA transgenic recipients. Given that there is
no difference in total number of clonotype-positive cells,
the putative CD441 double TCR cells would have to ex-
pand quite a bit and then become functionally nonrespon-
sive in the in vitro assay. It is also possible that tolerized
Figure 5. HA expression on BM-derived cells is not required for toler-
ance induction. C3-HA transgenic and NT mice were lethally irradiated
and reconstituted with BM prepared from either NT or C3-HA donors.
Clonotypic cells were retrieved 21 d after adoptive transfer from chimeric
recipients: open circles, NT ® NT (BM donor ® irradiated recipient);
closed circles, NT ® C3-HA; open squares, C3-HA ® NT; and closed
squares, 3-HA ® C3-HA. Proliferation assays were established as in Fig. 3
A. Two-color FACSÒ analysis indicated that equivalent numbers of clo-
notypic cells were present in the various chimeras (data not shown). Each
data point (mean 6 SD) is derived from two animals. This experiment
was representative of two independent trials (data not shown).1561 Adler et al.
cells may be dying off in subsequent weeks after the time
period that was analyzed. In fact, in other models of CD41
T cell tolerance induction to peripheral self-antigens, most
of the CD4 cells were found to be deleted at later time
points (although there was also evidence of residual anergic
cells) (34).
That BM-derived APCs expressing low levels of HA
might have been able to directly induce T cell tolerance is
consistent with previous studies indicating that the same
clonotypic T cells become tolerized when transferred into
transgenic mice expressing HA directly on hemopoietic
cells (35). Even more significantly, when BM-derived
APCs do not express HA themselves, they are still able to
induce T cell tolerance by means of a transfer pathway in
which they acquire the HA epitope from parenchymal
cells. The elucidation of this cross-tolerization pathway re-
solves several issues regarding tolerance induction in CD4
cells to peripherally expressed self-antigens. For example,
tolerance could be efficiently induced even if the parenchy-
mal cell type expressing the cognate antigen expresses little
or no class II MHC. Secondly, naive T cells that do not
normally traffic through nonlymphoid tissues (36) could in-
teract with tolerizing APCs in secondary lymphoid organs.
Although it has previously been shown in several systems
that BM-derived APCs can induce T cell tolerance in vivo
to either exogenous antigens (25, 37) or antigens expressed
directly on the APCs themselves (26, 35, 38), our study
firmly establishes that APCs can play a central role in main-
taining tolerance to parenchymally expressed self-antigens.
The class II–restricted HA epitope might enter the cross-
tolerance pathway as a function of its location within the
extracellular domain of a plasma membrane protein. Frag-
ments of the HA protein containing the class II epitope
might be released into the circulation through the action of
serum proteases, thus allowing APCs located in peripheral
lymphoid organs to acquire, process, and present the
epitope in a tolerogenic manner. Previously, it has been
shown that class II epitopes derived from HA expressed on
Figure 6. Tolerance induction
is mediated by BM-derived cells
which acquire HA via an antigen
transfer pathway. C3-HA trans-
genic and NT mice (F1, bxd)
were lethally irradiated and re-
constituted with BM from NT
donors of either the H-2d (HA-
restricting) or H-2b (nonrestrict-
ing) haplotype. (A) Naive HA-
specific CD4 cells (prepared
from 6.5 TCR transgenic mice
[F1, bxd]) were depleted of en-
dogenous class II positive cells
before adoptive transfer into par-
ent  ®  F1 chimeric recipients.
LN cells prepared from day 14
adoptive transfer were tested for
in vitro proliferative response to
HA peptide; H-2d ® H-2bxd/
HA (d ® HA, closed circles), H-2b
® H-2bxd/HA (b ® HA, closed
squares), H-2d ® H-2bxd/NT (d
® NT, open circles) and H-2b ®
H-2bxd/NT (b ® NT, open
squares). Experiments 1 and 2 are
two independent trials in which
each data point (mean 6 SD) is
derived from two separate mice,
except for the b ® NT group in
experiment 1, which represents a
single mouse. (B) Bar graph
showing average clonotype fre-
quencies from experiment 1
(mean  6  SD). (C) Representa-
tive histogram plots of CD44 ex-
pression on the surface of clono-
typic (C) and nonclonotypic
(NC) T cells in experiment 1.1562 CD41 T Cell Tolerance
pancreatic islet b cells can be presented on BM-derived
APCs (39). Furthermore, tolerance induction in a popula-
tion of clonotypic CD4 cells specific for the SV40 T anti-
gen appears to be initially manifested in the LNs draining
the pancreas in transgenic mice expressing T antigen under
the control of the rat insulin promoter (34). Although
mechanisms other than cross-tolerance might be operating
in this system, it is possible that T antigen (normally local-
ized in the nucleus) might be released from the b cells due
to an increased cell turnover resulting from the oncogenic
transformation initiated by T antigen itself. Interestingly,
cross-presentation of a class I–restricted self-epitope, de-
rived from a membrane-bound form of ovalbumin by
APCs, appears to play a role in inducing deletion of the
cognate CD8 cell population (40).
It is curious that the immune system would use a toler-
ance induction pathway for an epitope that is not normally
presented by the cells that express it. One possibility is that
it is a fail-safe mechanism that would prevent autoimmu-
nity if inflammation induces expression of class II MHC
molecules on antigen-expressing parenchymal cells. Argu-
ing against this possibility, parenchyma expressing class II
MHC in the absence of costimulatory molecules might in-
duce tolerance rather than autoimmunity (23). Alterna-
tively, anergized CD4 cells might play a role in regulating
the responses of CD8 or B cells to the same antigen whose
respective epitopes might be recognizable on the antigen-
expressing parenchyma.
Previous in vitro studies have suggested that anergy in-
duction results from TCR recognition of peptide–MHC
ligand in the absence of costimulation (22). The recent
finding that anergy can be prevented by blocking the B7-
CTLA4 pathway suggest that the induction of anergy in
vivo to exogenous antigens can be induced by cells ex-
pressing costimulatory signals (24). Although we currently
do not know whether costimulation plays a role in the
cross-tolerance pathway, our data do suggest that tolerance
induction in CD4 cells to peripheral self-antigens in vivo is
more complex than originally thought since T cells are not
directly tolerized by parenchyma expressing the cognate
epitope but rather by an intermediary APC. However, we
cannot rule out the existence of a second tolerization path-
way mediated by parenchymal cells expressing antigen and
class II MHC, but not costimulatory molecules. This path-
way might require either a higher T cell precursor fre-
quency or a longer period of time to develop than was used
in our current study. In fact, this type of tolerization path-
way has been observed in double transgenic mice express-
ing an allo-class II MHC on parenchymal cells (lacking co-
stimulatory activity) as well as the cognate clonotypic TCR
on a large proportion of its mature CD4 cells (23). In the
event that multiple pathways are able to induce tolerance in
vivo, cross-tolerance would probably be the dominant
pathway as parenchymal cells only express class II MHC
under conditions of inflammation, whereas cross-tolerance
would be operative constitutively.
Dissection of the cross-tolerance pathway will require
identification of the APC involved in mediating this phe-
nomenon. All three APC subtypes (B cells [25, 26], mac-
rophages [38], and dendritic cells [37, 41]) have been
shown in various systems to be capable of inducing T cell
tolerance. It will be particularly interesting to determine
whether the APC that mediates cross-tolerance is the same
as the APC that can activate T cells in the cross-priming
pathway used by certain tumor vaccines (42). One possibil-
ity is that one specific APC subtype is dedicated to induc-
ing tolerance while another activates T cells. Alternatively,
the same APC could induce either tolerance or activation
depending upon whether an appropriate secondary signal is
provided simultaneously. For tumor vaccines, expression of
antigen in conjunction with cytokine (43) would program
an APC to activate T cells. In the case of peripheral toler-
ance to self-antigens, the APC would acquire antigen from
parenchymal tissues in the absence of a second signal, thus
resulting in a tolerizing APC.
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